The Centers for Disease Control and Prevention (CDC) reported that carbapenem-resistant enterobacteriaceae (CRE) has increased over the last decade and most cases of resistance are associated with healthcare exposures. To slow the dissemination of CRE infections, local and state health departments need to take the lead in prevention efforts, according to CDC’s Morbidity and Mortality Weekly Report released on March 5.
The Centers for Disease Control and Prevention (CDC) reported that carbapenem-resistant enterobacteriaceae (CRE) has increased over the last decade and most cases of resistance are associated with healthcare exposures. To slow the dissemination of CRE infections, local and state health departments need to take the lead in prevention efforts, according to CDC’s Morbidity and Mortality Weekly Report released on March 5.
CRE have been reported in healthcare settings as a difficult infection to treat with high rates of mortality (40% to 50%). During the first half of 2012, 4.6% of acute-care hospitals reported CRE cases. Of these, 145 acute-care hospitals for short stays (3.9%) and 36 long-term care hospitals (17.8%) reported one or more infections with CRE among almost 4,000 acute-care hospitals in the United States that performed surveillance. Hospitals in the Northeast and those that were larger and teaching hospitals were more likely to report CRE.
The CRE isolates reported in 2001 included Klebsiella pneumoniae and oxytoca, Escherichia coli, and Enterobacter aerogenes and cloacae. The CRE isolates in 2011 included Klebsiella pneumonia, Escherichia coli, and Enterobacter aerogenes and cloacae. The Klebsilla species had the largest increase in CRE isolates from 2001 to 2011, from 1.6% to 10.4%.
In the hospital, the most common source for CRE was urine (almost 90%) and then blood at 10%. While most of the isolates were collected from cultures outside of the hospital, most of the community-associated CRE isolates had recently been exposed in a healthcare setting, the report noted.
Invasive infections with CRE, such as bloodstream infections, were the most dangerous, resulting in mortality rates of 40% or more.
Efforts to control multidrug-resistant organisms have been very successful in the past.
“State and local health departments are well positioned to lead CRE control efforts because of their expertise in surveillance and prevention and their ability to interact among all the healthcare facilities in their jurisdiction,” the report stated. “Six states have made CRE reportable, and three additional states are actively pursuing this option.”
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More